Growth Metrics

Definium Therapeutics (DFTX) Tax Provisions (2021)

Definium Therapeutics (DFTX) reported Tax Provisions of -$1.2 million for Q4 2021.

Definium Therapeutics (DFTX) has 1 years of Tax Provisions data on file, last reported at -$1.2 million in Q4 2021.

  • Quarterly Tax Provisions changed N/A year-over-year to -$1.2 million in Q4 2021, while the trailing twelve-month figure through Sep 2022 was -$1.2 million (changed N/A YoY) and the FY2021 annual result came in at -$1.2 million, changed N/A from the prior year.
  • Tax Provisions held at -$1.2 million in Q4 2021 per DFTX's latest filing.
  • Across five years, Tax Provisions topped out at -$1.2 million in Q4 2021 and bottomed at -$1.2 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Taxes (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -11.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -859,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 221.50 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - 216,000.00
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 104.00 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 15.66 Mn
10 Definium Therapeutics 2.42 Bn 2.06 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 -1.16 Mn